LAVA Therapeutics N.V.
LVTX
$1.62
$0.010.31%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | 4.99M | 4.99M | 11.98M | 7.35M | 7.40M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 4.99M | 4.99M | 11.98M | 7.35M | 7.40M |
| Cost of Revenue | 24.55M | 24.55M | 24.55M | 32.71M | 32.72M |
| Gross Profit | -19.56M | -19.56M | -12.57M | -25.37M | -25.33M |
| SG&A Expenses | 12.85M | 14.13M | 14.08M | 13.28M | 13.35M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 31.75M | 36.45M | 37.89M | 35.64M | 35.14M |
| Operating Income | -26.76M | -31.46M | -25.91M | -28.30M | -27.74M |
| Income Before Tax | -27.61M | -27.26M | -24.54M | -27.31M | -23.90M |
| Income Tax Expenses | 773.00K | 787.00K | 631.00K | 290.00K | 244.00K |
| Earnings from Continuing Operations | -28.38 | -28.05 | -25.17 | -27.60 | -24.14 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -28.38M | -28.05M | -25.17M | -27.60M | -24.14M |
| EBIT | -26.76M | -31.46M | -25.91M | -28.30M | -27.74M |
| EBITDA | -26.44M | -31.03M | -25.44M | -27.74M | -27.14M |
| EPS Basic | -1.06 | -1.04 | -0.94 | -1.03 | -0.91 |
| Normalized Basic EPS | -0.61 | -0.66 | -0.48 | -0.64 | -0.56 |
| EPS Diluted | -1.06 | -1.04 | -0.94 | -1.03 | -0.91 |
| Normalized Diluted EPS | -0.61 | -0.66 | -0.48 | -0.64 | -0.56 |
| Average Basic Shares Outstanding | 107.50M | 107.43M | 107.33M | 107.23M | 106.68M |
| Average Diluted Shares Outstanding | 107.50M | 107.43M | 107.33M | 107.23M | 106.68M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |